VIP Twitter chat on liver cancer next week

Anyone who tweets may want to get a few in at this online event. Attendees include lots of VIPs…but no VVA or other vet groups.

Image: PD Pixabay

Know Hepatitis: Reduce Liver Cancer Risk and Join a Liver Cancer Awareness Twitter Chat

Tuesday, Oct. 25, 2:00 p.m. (EST)

October is Liver Cancer Awareness Month and it’s time to “chat” about reducing liver cancer in people living with hepatitis B and C. *

On Tuesday, Oct. 25, representatives from Hep B United, CDC’s Division of Viral Hepatitis, and NASTAD (the National Alliance of State and Territorial Aids Directors) will co-host a twitter chat at 2 p.m. EST using the hashtag #liverchat.

Also participating are special guests from CDC’s Division of Cancer Prevention and Control, Prevent Cancer Foundation, and Dr. Katherine McGlynn of the National Cancer Institute. Dr. McGlynn is a Senior Investigator at the National Cancer Institute, Division of Cancer Epidemiology & Genetics, Metabolic Epidemiology Branch. She is a researcher and expert in hepatocellular carcinoma.

To see the topics to be discussed, and other confirmed attendees, go here: (link). I like

these three Qs especially as they relate to homeless vets. Experts– HUD sells houses for $1.00 to charities etc… Please, buy some for heaven’s sake! No one needs fancy when they’re sick and homeless.

Q4: What are the barriers that keep people from getting screened for viral hepatitis and how can they be addressed?
Q6: Why are some populations more vulnerable to viral hepatitis and liver cancer, and how do we address the disparities?
Q7: What can we do to raise awareness & educate vulnerable communities about viral hepatitis and its link to liver cancer?

I can think of a few comments/questions I’d like to make but alas, haven’t figured Twittering out yet. Maybe it’s time because this is a chance to advocate for stricken vets. What do you think about this opportunity? Interested?

* Sustained virologic response (SVR); cured by antivirals doesn’t mean you aren’t still living with HCV’s and/or treatments’ long term chronic adverse effects.